Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics Reports 2007 Results
March 14th, 2008
Allos Therapeutics, Inc. (Nasdaq:ALTH) reported results for its fiscal year ended December 31, 2007 and outlined its key objectives for 2008. For the year ended December 31, 2007, the Company reported a net loss of $39.4 million, or $0.60 per share, compared to a net loss of $30.2 million, or $0.55 per share, for 2006. For the year, net cash used in operating activities was $30.8 million. Cash, cash equivalents and investments in marketable securities as of December 31, 2007 totaled $57.8 million. "During 2007, we executed our strategic plan resulting in significant advancements in the development of PDX in hematologic malignancies and solid tumors," said Paul L. Berns,...
Source: Health Business Week (2008-03-14)
|
